What to Expect

• Considering Alpha-1 Testing
• Newly Diagnosed with Alpha-1
• Living With Alpha-1

Once you and your doctor have agreed on augmentation therapy, you'll want to understand what will be involved in the therapy process. Here is important information about what you can expect when your augmentation therapy begins.

You will receive your ARALAST through an infusion, which means that an intravenous (IV) line will be used to get the ARALAST into your bloodstream. The infusion will be administered by a healthcare professional, such as a doctor or nurse. Most people receive ARALAST infusions once a week.

Selecting a Location

Depending upon your insurance coverage, your personal preference, and what you and your healthcare provider think might be best for you, you may receive your infusions in:

• your home
• your workplace
• a hospital outpatient department
• a freestanding infusion center or clinic

If you decide to receive your ARALAST therapy at home or in your workplace, a specialized homecare company will help you with all the arrangements.

You and your healthcare provider can select the homecare company that best fits your needs. To learn more about the homecare companies available to ARALAST patients, visit the Home Care page of this website.

Home Care and Your Therapy

Once you have selected a homecare company, your healthcare provider will contact the company to begin the process.

First, you will receive a call from your specialized homecare agency – usually within a week of deciding that augmentation therapy is right for you. Together, you will set up the time and dates for your infusions.

When the homecare nurse arrives to administer your treatments, he or she will bring everything needed for your infusion. The complete infusion process, including set-up, usually takes about an hour.

Even though you will be getting infusions every week, you will continue to see your doctor regularly. Any questions you have about your therapy or care of your infusion site can be answered by your doctor, your homecare agency, and/or the nurse who administers your therapy.

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Please review the Important Safety Information and the Full Prescribing Information